Home>Topics>Stocks>Cadence Pharmaceuticals

Cadence Pharmaceuticals CADX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Mallinckrodt Continues Its Acquisition Binge With Questcor Merger

      Commentary

      Mon, 7 Apr 2014

      billion merger with Questcor. The deal comes less than a month after Mallinckrodt closed its acquisition of Cadence Pharmaceuticals . The transaction will be funded approximately 35% with debt financing, and 65% with shares of Mallinckrodt

    2. Recro Pharma IPO Could Be More Painful Than Expected

      Headlines

      Wed, 5 Mar 2014

      By Don Dion : Recro Pharma Inc. ( REPH ), a clinical stage pharmaceutical firm, developing non-opioid pain therapeutics, plans to raise $28 million in its upcoming IPO this week. The Malvern, Pennsylvania-based firm will offer 2.5 million shares at an expected price range of $10-$12 per share. If

    3. Mallinckrodt's Acquisition of Cadence Pharmaceuticals Looks Like a Stretch

      Commentary

      Tue, 11 Feb 2014

      Mallinckrodt announced today that is acquiring Cadence Pharmaceuticals for $1.3 billion. The deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business, but

    4. Cadence Pharma falls to life-low on disappointing results

      Headlines

      Fri, 4 May 2012

      (Reuters) - Cadence Pharmaceuticals Inc's shares fell to their life-low after the biopharmaceutical company reported a larger-than-expected first-quarter loss on costs related to the recall of its...

    5. Dropping Coverage of Cadence Pharmaceuticals

      Commentary

      Mon, 29 Aug 2011

      We are no longer providing equity research on Cadence Pharmaceuticals CADX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    6. 17 Highly Shorted Stocks Ready for a Squeeze

      Headlines

      Mon, 4 Apr 2011

      Kurtis Hemmerling submits: A high amount of short-selling may take place in a stock for a few reasons. One may be that analysts may have lowered thier rating or earnings forecasts for a stock. Margins may be sliding and the earning potential for the company is in serious doubt. Such fiscal problems

    7. Cadence's Fourth-Quarter Costs Beat Our Expectations

      Commentary

      Fri, 4 Mar 2011

      Cadence Pharmaceuticals CADX reported fourth-quarter results with costs coming in below our expectations. However, this did not have a material impact on

    8. New Morningstar Analyst Report - Cadence Pharmaceuticals , Inc.

      Stock Reports

      Wed, 23 Feb 2011

      provisions can favor executives over common shareholders. Cadence Pharmaceuticals in-licenses, develops, and markets drugs for the ..... regulations on pain medications could also harm sales. Cadence Pharmaceuticals has won Food and Drug Administration approval of its

    9. Approval for Cadence Pharma's Lead Drug

      Commentary

      Thu, 4 Nov 2010

      Cadence Pharmaceuticals CADX received Food and Drug Administration approval for lead drug candidate Ofirmev, an intravenous acetaminophen. At first glance

    10. Impending FDA Decision for Cadence Drug

      Commentary

      Mon, 4 Oct 2010

      We're maintaining our fair value on Cadence Pharmaceuticals CADX as we await a Food and Drug Administration decision on its lead drug candidate Ofirmev (formerly known as Acetavance). The agency has set an action date of November 4.

    « Prev123Next »
    Content Partners